Kronox Lab Sciences Latest Share Price (KRONOX)
TODAY IN ONE LINE
KRONOX surged 15.6% on above-average volume (158.2x avg), outperforming Nifty's 0.1% move, reaching near its 52-week high of ₹186.2.
With a market cap of ₹796.99 Cr., it trades at a P/E of 19.62. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Kronox Lab Sciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 26.7% YoY
- ●High Capital EfficiencyROCE of 36.0% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 26.8%
- ●Healthy Operating MarginsOPM is structurally strong at 33.9%
- ●High Promoter HoldingPromoters hold 74.2% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Kronox Lab Sciences News
What changed recently?
Recent events, corporate actions, and announcements.
Kronox Lab Sciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Kronox Lab Sciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Kronox Lab Sciences Limited trades at a P/E of 19.62× and P/B of 4.83×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Kronox Lab Sciences Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Kronox Lab Sciences Limited — derived from the latest tape, not yesterday's close.
Kronox Lab Sciences Limited last traded at ₹215.18 with an intraday range of ₹191–₹223.42 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹215.18| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 293.57 | +78.39 | +36.43% |
| R3 | 261.15 | +45.97 | +21.37% |
| R2 | 242.29 | +27.11 | +12.60% |
| R1 | 228.73 | +13.55 | +6.30% |
| PIVOT | 209.87 | -5.31 | -2.47% |
| CURRENT | 215.18 | — | — |
| S1 | 196.31 | -18.87 | -8.77% |
| S2 | 177.45 | -37.73 | -17.54% |
| S3 | 163.89 | -51.29 | -23.83% |
| S4 | 131.47 | -83.71 | -38.90% |
KRONOX is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹191–₹215
Trading Above opening range, showing Bullishness
Kronox Lab Sciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Kronox Lab Sciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Kronox Lab Sciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹796.99 Cr. and reported EPS of ₹7.45.
Kronox Lab Sciences segment analysis : revenue and profit mix.
Disclosed business segments at Kronox Lab Sciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Kronox Lab Sciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Kronox Lab Sciences Limited.
Our AI distills the core fundamental drivers supporting Kronox Lab Sciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Kronox Lab Sciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Debt-free balance sheet with D/E 0.0001x provides exceptional financial flexibility.
ROCE 36.00% and ROE 26.80% substantially exceed specialty chemicals sector benchmarks.
Operating margin 31.83% demonstrates superior pricing power and operational efficiency.
Promoter holding 74.21% ensures strong alignment with long-term shareholder interests.
P/E 20.30x trades below peer median, offering attractive valuation entry point.
Key Risks.
Latest quarterly EPS grew 26.7% YoY despite quarterly sales declining 3.57% YoY.
FII holdings collapsed from 1.56% to 0.03%, signaling foreign investor confidence concerns.
Heavy capex spending generated negative investing cash flow of ₹155.27 Cr recently.
Modest dividend yield 0.33% limits income appeal for yield-focused investors.
Market cap ₹563 Cr exposes company to liquidity and valuation volatility risks.
Flip Conditions.
Valuation risk. a P/E above 26 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 22% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.17%.
Kronox Lab Sciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Kronox Lab Sciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Kronox Lab Sciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Kronox Lab Sciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Kronox Lab Sciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Kronox Lab Sciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Kronox Lab Sciences Limited stood at 7.1% of traded volume, against a 20-day average of 44.8%.
Kronox Lab Sciences announcements: results, concalls, ratings, M&A.
Filings Kronox Lab Sciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Kronox Lab Sciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 43 documents below.
Updates
Kronox Lab Sciences Limited has informed the Exchange regarding ' Announcement under Regulation 30 (LODR)-Acquisition'.
Public Announcement-Open Offer
IIFL Capital Services ltd, Indo Borax & Chemicals Ltd and Zenrock Chemicals Pvt Ltd has Submitted to the Exchange PUBLIC ANNOUNCEMENT FOR THE…
Updates
Kronox Lab Sciences Limited has informed the Exchange regarding 'Press Release'.
Updates
Kronox Lab Sciences Limited has informed the Exchange regarding 'Promoters Infromed The Company About The SPA'.
Updates
Kronox Lab Sciences Limited has informed the Exchange regarding 'Announcement Of SPA Executed By Promoter'.
Kronox Lab Sciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Kronox Lab Sciences has declared, sequenced by announce and record date.
Kronox Lab Sciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Kronox Lab Sciences Limited: business, sector, key facts.
What Kronox Lab Sciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Kronox Lab Sciences Limited operates in the Specialty Chemicals industry under the Chemicals sector, listed as NSE: KRONOX, BSE: 544187.
Kronox Lab Sciences Limited is a chemical manufacturing and distribution company operating in India and globally. Their core business centers around the production and sale of a wide range of chemicals, catering to various industrial sectors. This includes substantial volumes of fine chemicals, inorganic chemicals, phosphates, and metallic chemicals.
A significant portion of Kronox's business involves supplying bulk reagents. These reagents are categorized based on their purity levels, encompassing ACS reagents and those classified as LR, AR, and GR grades. This signifies a focus on supplying chemicals for various applications requiring diverse purity standards, ranging from basic laboratory use to more stringent requirements for specific industries.
Beyond bulk reagents, Kronox offers a comprehensive portfolio of bulk ingredients tailored for multiple sectors. This includes key components for oral care products, pharmaceutical preparations (pharmacopoeia grade), food and nutraceutical products, personal care and cosmetic items, and veterinary pharmaceuticals and animal health products. This diversification demonstrates their capacity to serve a broad spectrum of industries with specialized chemical requirements.
Further enhancing their product range, Kronox specializes in the manufacture of specialty chemicals. This segment incorporates a diverse array of compounds, including tartrates, citrates, hypophosphites, phosphates, hydroxides, EDTA and its derivatives, ultra-high-purity chemicals, and custom-synthesized chemicals formulated to meet specific customer specifications. The inclusion of anhydrous versions of certain chemicals highlights their capacity to provide specialized chemical forms suited for niche applications.
Established in 2008 and headquartered in Vadodara, India, Kronox has built a significant presence in the chemical industry through its diverse product portfolio and ability to cater to the varying needs of multiple sectors. Their focus on both bulk and specialty chemicals, coupled with their commitment to meeting stringent purity standards, solidifies their position within the Indian and international chemical markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarti Industries (AARTIIND) Share PricePeer
- Aarti Surfactants (AARTISURF) Share PricePeer
- Archean Chemical Industries (ACI) Share PricePeer
- Aether Industries (AETHER) Share PricePeer
- Alkali Metals (ALKALI) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
Questions investors ask about Kronox Lab Sciences Limited (KRONOX).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Kronox Lab Sciences Limited (KRONOX)?
The current share price of Kronox Lab Sciences Limited (KRONOX) is ₹215.18. Today, the stock has gained by ₹28.99 (15.57%), trading in a range of ₹191.00 to ₹223.42. The stock opened at ₹191.00 with a trading volume of 2,43,28,555 shares.
02Is Kronox Lab Sciences Limited stock a good investment for long-term?
Kronox Lab Sciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹796.99 Cr., P/E ratio of 19.62, ROE of 26.8%, and ROCE of 36%. The dividend yield stands at 0.33%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Kronox Lab Sciences Limited stock?
The 52-week high price of Kronox Lab Sciences Limited (KRONOX) is ₹186.19, while the 52-week low is ₹96.00. Currently trading at ₹215.18, the stock is 124.15% above its 52-week low and -15.57% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Kronox Lab Sciences Limited stock at the current price?
Whether to buy Kronox Lab Sciences Limited stock at ₹215.18 depends on multiple factors. The stock is currently trading with a P/E ratio of 19.62 and P/B ratio of 4.83. Today's performance shows a gain of 15.57%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Kronox Lab Sciences Limited and when is the next dividend?
Kronox Lab Sciences Limited offers a dividend yield of 0.33%, which means for every ₹100 invested at the current price of ₹215.18, you can expect to receive approximately ₹0.33 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Kronox Lab Sciences Limited?
Kronox Lab Sciences Limited's key financial metrics include: P/E Ratio: 19.62, P/B Ratio: 4.83, ROE: 26.8%, ROCE: 36%, Dividend Yield: 0.33%, EPS: ₹7.45, Book Value: ₹31.64, and Debt-to-Equity: 0.01. The company's market cap stands at ₹796.99 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Kronox Lab Sciences Limited stock performing today in the market?
Kronox Lab Sciences Limited stock opened at ₹191.00 and is currently trading at ₹215.18, showing a gain of ₹28.99 (15.57%). The intraday high is ₹223.42 and low is ₹191.00. The trading volume stands at 2,43,28,555 shares, indicating strong market participation today.
08What is the P/E ratio of Kronox Lab Sciences Limited and what does it indicate?
Kronox Lab Sciences Limited has a Price-to-Earnings (P/E) ratio of 19.62, which means investors are willing to pay 19.62 for every ₹1 of earnings. With an EPS of ₹7.45, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Kronox Lab Sciences Limited (KRONOX) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.